NEW YORK (GenomeWeb) – Abbott reported on Wednesday that its fourth quarter diagnostic revenues grew 3 percent year over year, despite an unfavorable 1 percent effect from foreign exchange.

Its molecular diagnostics revenues dropped 8 percent driven by a planned scale down of its genetics business that offset growth in infectious disease testing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.